A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Status:
Recruiting
Trial end date:
2025-09-09
Target enrollment:
Participant gender:
Summary
This study is done to find out whether the medicine, semaglutide, has a positive effect on
early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not
contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have
17 clinic visits and 1 phone call with the study doctor. The study includes various tests and
scans. At 10 of the clinic visits participants will have blood samples taken.
Participants must have a study partner, who is willing to take part in the study.
Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study
period.
A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study
will be performed on a selection of sites based on their experience with CSF sampling and
willingness to participate in this sub-study. The endpoints related to this sub-study are
exploratory only.